Compare Amgen, Inc. (AMGN) vs Comfort Systems USA Inc (FIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Comfort Systems USA Inc — how do they compare? Amgen, Inc. trades at $356.38 (market cap $196.12B), while Comfort Systems USA Inc trades at $1,717.1 (market cap $61.82B). The key difference: Amgen, Inc. is far larger — about 3.2× Comfort Systems USA Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | FIX | |
|---|---|---|
Market Cap | $196.12B | $61.82B |
Sector | Health | Technology |
52-Week High | $388.16 | $2.07K |
52-Week Low | $271.18 | $532.14 |
Enterprise Value | $241.41B | $61.11B |
Dividend Yield | 2.77% | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Comfort Systems USA (FIX) trades at $1,756.09, down 1.42% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with consistent earnings beats, robust revenue growth to $10.1B in 2026, and high profitability margins. Recent news highlights expansion in modular capabilities and leadership transitions, while analyst consensus remains bullish with a $2,100 price target.
Outlook is positive driven by AI infrastructure demand and a record backlog, though premium valuation multiples pose a risk. Execution of growth initiatives and macroeconomic conditions are key watchpoints for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →
